Rubbish Check
Forbes Business · August 20, 2026
source“Moderna Stock Plunges 25%-Wiping Out $18 Billion After Historic Cancer Vaccine Breakthrough”
R6/ 10
Spin-heavy
Rubbish Rating — 1 = base fact, 10 = pure rubbish
12345678910
In short
Rubbish Talk rates Forbes' claim that Moderna's cancer-vaccine breakthrough triggered a $18 billion stock "plunge" a 6/10, because the headline omits that shares had just surged 176% the day before and remained far above pre-announcement levels.
The Verdict
Spin-heavy. The headline states a true number, a 25% drop and $18 billion of paper value gone, but strips out the one fact that changes everything: that "loss" followed a 176% overnight surge, and even after the pullback the stock sat at roughly $129, still well above where it traded before the trial results. Framing profit-taking after a record rally as a story about a breakthrough being punished inverts the actual sequence of events.
What actually happened
Moderna's shares jumped 176% on Wednesday after the company reported that its personalized mRNA cancer vaccine, paired with Merck's Keytruda, cut melanoma recurrence and extended time patients stayed cancer-free. On Thursday, shares gave back more than 25% as investors took profits, though Wall Street's reaction to the underlying data remained positive.
Key facts
- Shares fell more than 25% to around $129 Thursday, down from a Wednesday close above $174 after a 176% one-day surge.
- Market valuation dropped from Wednesday's $69.6 billion close to $51.5 billion Thursday, a decline of over $18 billion, but still far above pre-surge levels.
- Bank of America's Alec Stranahan raised his price target more than fourfold, from $40 to $170, calling the trial data a "watershed moment" for Moderna.
- Stranahan flagged an open caveat: analysts "still don't know how much better" the combo drug is than Keytruda alone, and more testing is needed.
- Co-founder Thomas Langer's stake rose from $730 million to $1.7 billion on the Wednesday surge; CEO Stéphane Bancel's fortune rose $2.5 billion before falling $1.3 billion Thursday, still leaving him $1.2 billion richer than before the announcement.
What to watch for
- Watch whether Moderna's stock stabilizes near $129-150 in the following sessions, which would confirm this was profit-taking rather than a reversal of the market's view on the drug.
- Expected trial expansions into non-small-cell lung and bladder cancer will be the next real catalyst; any delay or weak data there is the genuine risk, not Thursday's dip.
- Watch for follow-up coverage that quietly drops the "plunge" framing once it's clear the stock never fell below its pre-announcement price.
About this scoreThe R-Score is Rubbish Talk's editorial opinion on how far a headline's framing sits from what the underlying facts support. It is a judgement about presentation and emphasis, not an allegation that any outlet has acted dishonestly. Every figure we rely on is linked under Receipts so you can check it yourself.
